15,327 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Purchased by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 15,327 shares of the medical research company's stock, valued at approximately $2,833,000.

A number of other hedge funds have also modified their holdings of the stock. EP Wealth Advisors LLC acquired a new position in Charles River Laboratories International in the 3rd quarter worth about $273,000. National Bank of Canada FI increased its holdings in Charles River Laboratories International by 45.4% in the third quarter. National Bank of Canada FI now owns 21,216 shares of the medical research company's stock worth $4,179,000 after buying an additional 6,627 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its position in Charles River Laboratories International by 13.7% during the third quarter. Nomura Asset Management Co. Ltd. now owns 15,592 shares of the medical research company's stock valued at $3,071,000 after acquiring an additional 1,882 shares in the last quarter. M&T Bank Corp lifted its stake in Charles River Laboratories International by 3.4% in the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after acquiring an additional 66 shares during the last quarter. Finally, Neo Ivy Capital Management bought a new stake in Charles River Laboratories International in the third quarter worth approximately $966,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company's stock, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Birgit Girshick purchased 1,514 shares of the business's stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Mizuho cut their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Morgan Stanley decreased their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $190.00 to $170.00 in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $182.00.

Charles River Laboratories International Stock Performance

NYSE CRL traded down $1.18 during midday trading on Tuesday, hitting $105.42. The company had a trading volume of 628,756 shares, compared to its average volume of 870,291. The firm has a fifty day simple moving average of $155.52 and a two-hundred day simple moving average of $176.21. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a market cap of $5.18 billion, a price-to-earnings ratio of 702.80, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period last year, the business earned $2.46 earnings per share. Equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).